Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

ESMO21: MONALEESA-2 trial demonstrates overall survival benefit

Written by Jade Parker, Senior Editor


According to the MONALEESA-2 trial, which was recently presented at the ESMO Congress 2021 (16−21 September 2021; Virtual), adding a CDK 4/6 inhibitor to first-line hormonal treatment extends survival by 1 year for postmenopausal women with HR-positive, HER2 negative advanced breast cancer. The Phase III randomized clinical trial included 668 patients who were randomly allocated ribociclib plus the aromatase inhibitor letrozole or placebo plus letrozole. Patients who has previously received a CDK 4/6 inhibitor, chemotherapy or endocrine therapy in the advanced setting were excluded. The median progression free survival was 25.3 months for ribociclib plus letrozole and 16 months for...

To view this content, please register now for access

It's completely free